Anne Katrine Eek1, Erik Øie2, Anne Gerd Granas3. 1. Regional Medicines Information & Pharmacovigilance Centre (RELIS), Oslo University Hospital HF Rikshospitalet, PO Box 4950 Nydalen, 0424, Oslo, Norway. ankeek@ous-hf.no. 2. Diakonhjemmet Hospital, Diakonveien 12, 0370, Oslo, Norway. 3. School of Pharmacy, University of Oslo, PO Box 1072 Blindern, 0316, Oslo, Norway.
Abstract
PURPOSE: The development of non-vitamin K-dependent oral anticoagulants (NOACs) is a new alternative to treatment with warfarin. The purpose of this study was to explore drug prescription decisions of NOACs or warfarin from hospital physicians in cardiovascular departments. METHODS: A qualitative study with focus group interviews was conducted in three different hospitals. The interview guide explored the background of prescribing anticoagulants (warfarin, dabigatran, rivaroxaban, and apixaban) and experiences with effect and side-effects they had observed in patients. RESULTS: The systematic text condensation eluded four main themes: when to prescribe NOACs, concern about side-effects, pharmaceutical properties and patient adherence, and prescribing policy and intra-professional communication. All available anticoagulants were prescribed. However, no specific NOAC was preferred. Factors perceived as contraindications for NOACs varied among the doctors. Most had observed side-effects of NOACs; however, these rarely influenced prescribing decisions due to small differences in safety profiles. Few drug-drug interactions and fixed daily doses made NOACs easy to prescribe; but some doctors had experienced lack of drug effect for some patients. Non-adherence with NOACs was harder to spot. Some different prescribing cultures had evolved between the different hospitals and between general practitioners. CONCLUSION: The hospital physicians chose anticoagulants based on patient conditions as renal function, bleeding risks, and drug interactions being the most common taken into account. They could not say which NOAC was best, and wish that future studies could compare the different NOACs, and not just compare with warfarin.
PURPOSE: The development of non-vitamin K-dependent oral anticoagulants (NOACs) is a new alternative to treatment with warfarin. The purpose of this study was to explore drug prescription decisions of NOACs or warfarin from hospital physicians in cardiovascular departments. METHODS: A qualitative study with focus group interviews was conducted in three different hospitals. The interview guide explored the background of prescribing anticoagulants (warfarin, dabigatran, rivaroxaban, and apixaban) and experiences with effect and side-effects they had observed in patients. RESULTS: The systematic text condensation eluded four main themes: when to prescribe NOACs, concern about side-effects, pharmaceutical properties and patient adherence, and prescribing policy and intra-professional communication. All available anticoagulants were prescribed. However, no specific NOAC was preferred. Factors perceived as contraindications for NOACs varied among the doctors. Most had observed side-effects of NOACs; however, these rarely influenced prescribing decisions due to small differences in safety profiles. Few drug-drug interactions and fixed daily doses made NOACs easy to prescribe; but some doctors had experienced lack of drug effect for some patients. Non-adherence with NOACs was harder to spot. Some different prescribing cultures had evolved between the different hospitals and between general practitioners. CONCLUSION: The hospital physicians chose anticoagulants based on patient conditions as renal function, bleeding risks, and drug interactions being the most common taken into account. They could not say which NOAC was best, and wish that future studies could compare the different NOACs, and not just compare with warfarin.
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castellá; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Rev Esp Cardiol (Engl Ed) Date: 2017-01
Authors: Benjamin A Steinberg; Peter Shrader; Laine Thomas; Jack Ansell; Gregg C Fonarow; Bernard J Gersh; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; James Reiffel; Daniel E Singer; Eric D Peterson; Jonathan P Piccini Journal: J Am Coll Cardiol Date: 2016-12-20 Impact factor: 24.094
Authors: Antonio L Dans; Stuart J Connolly; Lars Wallentin; Sean Yang; Juliet Nakamya; Martina Brueckmann; Michael Ezekowitz; Jonas Oldgren; John W Eikelboom; Paul A Reilly; Salim Yusuf Journal: Circulation Date: 2012-12-27 Impact factor: 29.690
Authors: A John Camm; Gabriele Accetta; Giuseppe Ambrosio; Dan Atar; Jean-Pierre Bassand; Eivind Berge; Frank Cools; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Gloria Kayani; Yukihiro Koretsune; Lorenzo G Mantovani; Frank Misselwitz; Seil Oh; Alexander G G Turpie; Freek W A Verheugt; Ajay K Kakkar Journal: Heart Date: 2016-09-19 Impact factor: 5.994
Authors: Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Hans-Christoph Diener; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof Journal: Eur Heart J Date: 2017-07-14 Impact factor: 29.983